Governing Through the Life Sciences Capital Crunch: Board Discipline, Value Inflection, and Leadership Readiness

This program examined the consequential governance decisions life sciences boards face when capital is limited, scientific timelines are uncertain, and execution risk can materially affect enterprise value. The discussion focused on the board’s responsibility to provide disciplined oversight of cash runway, capital allocation, scientific de-risking, management readiness, investor readiness, and strategic alternatives.

Directors considered the questions that should be addressed before additional capital, time, or resources are committed: whether the company had a credible path to its next value-inflection point, whether key scientific and commercial milestones were sufficiently validated, whether leadership was prepared for the next stage, and whether the board had the expertise and independence required to challenge assumptions and guide critical decisions.

Attendees left with practical boardroom frameworks to strengthen oversight, support sound stage-gate decision-making, and protect long-term value when scientific promise, capital constraints, and execution risk converged.